DNA (Cytosine-C5) methyltransferase inhibition by oligodeoxyribonucleotides containing 2-(1H)-pyrimidinone (zebularine aglycon) at the enzymatic target site by Van Bemmel, Dana M. et al.
DNA (Cytosine-C5) Methyltransferase Inhibition by
Oligodeoxyribonucleotides Containing 2-(1H)-Pyrimidinone
(Zebularine Aglycon) at the Enzymatic Target Site
Dana M. van Bemmela,1,*, Adam S. Branka,2, Ramon Eritjac, Victor E. Marquezd, and Judith
K. Christmana,b
aDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center,
Omaha, NE 68198-5870, USA
bUNMC/Eppley Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198-5870,
USA
cCentro de Investigacion y Desarrolo, CSIC, E-08034 Barcelona, Spain
dLaboratory of Medical Chemistry, Center for Cancer Research, National Cancer Institute at
Frederick, 376 Boyles St, Frederick MD 21702, USA
Abstract
Aberrant cytosine methylation in promoter regions leads to gene silencing associated with cancer
progression. A number of DNA methyltransferase inhibitors are known to reactivate silenced genes;
including 5-azacytidine and 2-(1H)-pyrimidinone riboside (zebularine). Zebularine is a more stable,
less cytotoxic inhibitor compared to 5-azacytidine. To determine the mechanistic basis for this
difference, we carried out a detailed comparisons of the interaction between purified DNA
methyltransferases and oligodeoxyribonucleotides (ODNs) containing either 5-azacytosine or 2-
(1H)-pyrimidinone in place of the cytosine targeted for methylation. When incorporated into small
ODNs, the rate of C5 DNA methyltransferase inhibition by both nucleosides is essentially identical.
However, the stability and reversibility of the enzyme complex in the absence and presence of
cofactor differs. 5-Azacytosine ODNs form complexes with C5 DNA methyltransferases that are
irreversible when the 5-azacytosine ring is intact. ODNs containing 2-(1H)-pyrimidinone at the
enzymatic target site are competitive inhibitors of both prokaryotic and mammalian DNA C5
methyltransferases. We determined that the ternary complexes between the enzymes, 2-(1H)-
pyrimidinone inhibitor, and the cofactor S-adenosyl methionine are maintained through the formation
of a reversible covalent interaction. The differing stability and reversibility of the covalent bonds
may partially account for the observed differences in cytotoxicity between zebularine and 5-
azacytidine inhibitors.
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1. Introduction
Methylation of cytosine residues in DNA provides epigenetic information that can lead to gene
silencing during embryonic development [1-3] and the progression of cancer [4]. Since these
processes mediated by DNA methylation can be reversed when DNA replication occurs in the
absence of maintenance methylation, inhibitors of DNA methyltransferases are attractive
candidate drugs with the potential to reestablish antiproliferative signals and other critical
cellular functions that are abnormally silenced in tumor cells by DNA methylation.
Among the first specific inhibitors of DNA (cytosine C5)-methyltransferases (DNA C5-
MTases) described were cytidine analogs with nitrogen replacing C5 of the pyrimidine ring
(5-azacytidine (ZCyd) and 5-aza-2'-deoxycytidine (ZdCyd) [5,6]). When incorporated into
DNA in place of the cytidine (Cyd) targeted for methylation, these compounds are efficient
suicide inhibitors of DNA C5-MTases both in vivo [6-12] and in vitro [10-12]. ZCyd is
phosphorylated by uridine-cytidine kinase and can be incorporated into both RNA and DNA
whereas ZdCyd, which is phosphorylated by deoxycytidine kinase, is only incorporated into
DNA [13,14]. Once incorporated into DNA, azanucleoside analogs can effectively deplete the
cell of active enzyme by forming irreversible covalent adducts with DNA C5-MTases, resulting
in global hypomethylation. Despite the initial success of these agents for treating sickle cell
anemia, myelodysplastic syndrome, and a number of other cancers [15-20], there are serious
treatment-associated side effects. These include myelotoxicity and DNA mutations due to
incorporation of the nucleosides into genomic DNA [21], a potential factor in cancer
recurrence. Zebularine [2-(1H) pyrimidinone riboside] is a highly stable cytidine analog that
is significantly less toxic than ZdCyd (Figure 1). First identified as a bacteriostat [22],
zebularine was later found to act as a transition state inhibitor of cytidine deaminase (CDA)
[23-27].
At high micromolar concentrations zebularine has been shown to inhibit mammalian DNA C5-
MTases in cultured cells and mammalian tumors after prolonged exposure [28-30]. In vitro
studies have demonstrated the formation of stable inhibitory complexes between the bacterial
DNA C5-MTases M.HgaI and M.MspI and synthetic oligodeoxyribonucleotides (ODNs) with
the 2-(1H) pyrimidinone (2P) replacing C in their recognition site [30,31].
In vivo experiments revealed several logs difference in potency between ZdCyd and zebularine
on mammalian DNA methylation [28,29], but no published studies have directly compared the
interactions between Dnmt1 and DNA containing the two analogs. Therefore, we sought to
directly compare the potency and inhibitory mechanisms of DNA containing ZdCyt or 2P on
Dnmt1. We synthesized small ODN inhibitors containing either ZdCyt or 2P in place of the
target C study DNA C5-MTase inactivation. Our analysis included determination of the
kinetics of inhibition, thermal stability of complexes, and rate of dissociation in the presence
and absence of cofactors. Here, we report that ODNs containing 2P at the enzymatic target site
(Figure 2) are competitive inhibitors of both prokaryotic (M.HhaI) and mammalian DNA C5-
MTases (Dnmt1). Moreover, we determined that the ternary complexes between M.HhaI:2P-
ODN:S-adenosyl methionine (AdoMet) and Dnmt1:DM72P18:AdoMet are maintained through
the formation of a reversible covalent interaction.
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2. Materials and Methods
2.1 Oligodeoxyribonucleotide synthesis and annealing
Single-stranded (ss) ODNs containing 2P or ZCyt were synthesized as previously described
[32-34]. Each ODN was resuspended in Tris-EDTA, pH 8.0 and stored at -20°C (See Figure
2 for sequences). Double stranded (ds) ODN inhibitors of M.HhaI were formed by annealing
1 μg of each 13mer at 65 °C for 10 min and slowly cooling to ~45 °C over a period of 60 min.
2.2 Enzyme purification
M.HhaI was overexpressed in Escherichia coli strain ER1727 containing the pUHE25HhaI
plasmid (generously provided by Dr. S. Kumar, New England Biolabs) and purified as
described previously [35] using a HiTrap Sepharose SP HP column (cation exchange,
Amersham Biosciences, Piscataway, NJ). Purified recombinant Dnmt1 was isolated as
described previously [36].
2.3 Assays determining inhibitor potency
The procedure for measuring the rate of inactivation for M.HhaI has been previously described
in detail [34]. Briefly, reaction mixtures containing increasing concentrations of substrate
(AMp:A') were incubated at 37 °C in the absence or presence of ODN inhibitor (Figure 2).
Reactions were terminated after 5 min, a time point within the linear range of the assay.
Incorporation of methyl-H3 into DNA was quantified by liquid scintillation counting [37,38].
Each reaction was performed in duplicate. Error bars indicate standard error from the mean of
three independent experiments. The Km and Vmax data were determined using Graph Pad 3.0
software. A Lineweaver-Burk plot of the resulting data was prepared to determine kI values.
Dnmt1 inactivation reactions containing 0.4-0.6 μM enzyme were pre-incubated with 1-80
μM ODN inhibitor (Figure 2) for 0-4 min at 22 °C in imidazole buffer (100 mM imidazole,
pH 7.5, 20 mM EDTA) containing 1.3 μM DM7 (substrate), 50 μM AdoMet, and 0.1 mg/ml
BSA. Duplicate 1 μl aliquots were removed after specified times of pre-incubation and diluted
with 49 μl of assay mixture containing 0.2 mg/ml BSA, 1.2 μM AdoMet, 0.1 μg poly dI-
dC:dIdC (~3.45μM dinucleotide), and 0.8 μM 3H-AdoMet (specific activity 3015.5 GBq/
mmol) in imidazole buffer. The diluted reactions were incubated for an additional 60 min at
37 °C to determine the amount of Dnmt1 activity remaining. Substrate methylation was
quantified as described above.
For each concentration of inhibitor, the amount of remaining enzymatic activity was plotted
versus the time of pre-incubation. The t1/2, or time necessary for each concentration of inhibitor
to reduce the total activity by one-half was calculated using a fourth order polynomial
regression. The t1/2 value was then plotted versus the inverse of the concentration of inhibitor,
where kinactivation = ln2/slope. The KI was extrapolated from the resulting graph, with kI = -1/
x-intercept.
2.4 Binding Assays
2.4.1 SDS-PAGE analysis of M.HhaI-ODN Complexes—Reaction mixtures
containing 32P-end-labeled ODN (50 nM), M.HhaI (2.5 nM), and cofactor (100-200 μM) in
Methylation Reaction (MR) buffer (50 mM Tris pH 7.5, 10 mM EDTA, and 5 mM β-
mercaptoethanol (BME)) were incubated at 37 °C for 1 h. Reactions were brought to a final
concentration of 10% (v/v) glycerol, 1% (v/v) SDS, and 1% (v/v) BME and incubated at the
indicated temperatures for 5 min. They were then loaded directly onto a 6% SDS-
polyacrylamide gel and electrophoresed at 200 V for 60 min at 4 °C. Dried gels were
autoradiographed by exposure to Kodak X-OMAT LS film overnight.
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2.4.2 SDS-PAGE analysis of Dnmt1-ODN complexes—Reactions containing 32P-end-
labeled ODN (1 μM), Dnmt1 (0.4 μM), and cofactor (100-200 μM) in imidazole buffer were
incubated at 37 °C for 1 h. Prior to heating, reactions were brought to concentrations of 1% (v/
v) SDS and 1% (v/v) BME in SDS loading buffer and incubated at the indicated temperatures
for 5 min. Samples were loaded directly onto a 6%-SDS-polyacrylamide gel, and
electrophoresed at 200 V for 3 h (or until the dye front reached the bottom of the gel) at 4 °C.
Dried gels were autoradiographed by exposure to Kodak X-OMAT LS film overnight.
2.4.3 Non-denaturing gel shift assay—Binding reaction mixtures containing 45
nM 32P-end labeled ds 2P-ODN (Figure 2), 108 nM M.HhaI, 75 ng poly dAdT:dAdT (6 μM
dAdT dinucleotide), and 100 μM cofactor (as indicated in Figure 5) in MR buffer containing
13% (v/v) glycerol were incubated at 22 °C for 30 min as described [38]. After 30 min, one
hundred fold excess of unlabeled, ds 2P-ODN (4.5 μM) was added to each binding reaction
and incubations were continued at 22 °C for the indicated times. Enzyme-ODN complexes
were subjected to electrophoresis at 150 V for 2-3 h on a 10% (w/v) native polyacrylamide gel
that had been pre-electrophoresed at 100 V for 1 h in TBE buffer (89 mM Tris borate (pH 8.0),
2 mM EDTA).
Gels were dried and the enzyme-32P-ODN complex quantified by PhosphoImager (Typhoon,
Amersham) analysis. The percent ODN in the complex was determined for each sample by
dividing the signal in the band containing complex by the sum of the signals from bands
containing free ODN and enzyme-ODN complex and multiplying by 100. For dissociation
analysis, the natural log of the percent ODN bound in enzyme-ODN complex was plotted
against the time of incubation in the presences of unlabeled competitor. The (-) slope of this
plot is equal to the koff and t1/2 (=0.693/koff) was calculated.
3. Results
3.1 M.HhaI inhibition by 2P- and ZCyt-ODNs
The ODNs used as substrates or inhibitors in this study (Figure 2) were synthesized by standard,
published methods [33-38]. The ability of 2P-ODN to inhibit C5-MTases was compared with
that of ZCyt-ODN. Both the bacterial M.HhaI and Dnmt1 were efficiently inhibited by 2P-
ODN. The IC50, or concentration at which 50% of the enzymatic activity of was inhibited by
2P-ODN is nearly identical to that of the ZCyt-ODN for both M.HhaI (~20nM or 2.3 nmoles/
nmole enzyme) and Dnmt1 (~240nM or 2.5 nmoles/nmol enzyme) (See Figure S1,
Supplemental material). This result demonstrates that once 2-(1H)-pyrimidinone (2P) or 5-
aza-2'-deoxycytosine (ZCyt) are incorporated into DNA in place of C in CpG sites, they are
equally potent inhibitors of both M.HhaI and Dnmt1.
While this type of assay is a convenient method for directly comparing DNA C5-MTase
inhibitors, it does not provide information about mechanism. Therefore, rate assays were used
to determine Michaelis-Menten kinetic constants for M.HhaI. Increasing concentrations of the
substrate AMp:A′ were mixed with the indicated concentrations of inhibitor (0-76 nM).
Reactions were initiated by the addition of M.HhaI (8.6 μM), and the rate of incorporation of
radiolabeled methyl from [methyl-3H]AdoMet during a 5 min reaction was determined
(Materials and Methods). A plot of the rate of incorporation (nM/min) vs. the concentration of
AMp:A′ substrate demonstrates that the 2P-ODN is an effective inhibitor of M. HhaI activity
in vitro (Figure 3A and Figure S2, Supplemental Material for corresponding Lineweaver-Burk
plot). This nonlinear regression model and a Hanes-Woolf plot (Figure 3B) both indicate that
the apparent Vmax of the reaction is unchanged while the Km increases with the increase in
inhibitor concentration. The apparent equilibrium constant for inhibitor binding (ki) of the 2P-
ODN was 9.89 ± 0.56 nM compared to 4.3 ± 0.65 nM for ZCyt ODN. This result is typical of
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competitive inhibitors that display a high affinity for the catalytic pocket of the targeted
enzyme.
3.2 Dnmt1 inhibition by 2P- and ZCyt-ODN's
Dnmt1 is a processive enzyme with a catalytic rate 10-100 fold lower than M.HhaI [36,39]. In
addition, interaction of substrate DNA with an allosteric site in the Dnmt1 amino terminal
domain can lead to an initial lag in rate of methylation that limits the use of Michaels-Menten
kinetic analysis [39]. As an alternative approach, inhibition of Dnmt1 by DM72P18 and
DM7ZdCyt18 was characterized by determining kinactivation (maximal rate of enzyme
inactivation) and apparent kI (the inhibitor concentration that supports half the maximal rate
of enzyme inactivation) [40]. Results for DM72P18 are shown in Figure 4A. Dnmt1 was pre-
incubated with increasing amounts of this ODN for the indicated times and the amount of active
enzyme remaining was determined by diluting aliquots of the pre-incubation mixture into an
assay mixture containing excess DM7 substrate and radiolabeled [methyl-3H]AdoMet. The
kI, was determined to be 2.005 ± 0.405 μM (Figure 4B). This is ~ 4.6 fold lower than that
observed with DM7ZCyt18 [34] suggesting that Dnmt1 has a somewhat higher affinity for 2P
than for ZCyt. The rate of inactivation (kinact) determined by plotting 1/concentration of ODN
vs. the time required for half-maximal reduction in activity (t1/2) was 2.65 ± 0.405 min-1 for
the DM7 2P18 ODN, in the same range as that reported for DM7ZCyt18 (kinact= 0.96 ± 0.23
min-1) [41]. These results indicate that once 2P is incorporated into a DNA substrate in place
of the target C, it displays high affinity for DNA C5-MTases and is comparable to DZCyt in
its ability to inhibit DNA methylation[38].
3.3 Enzyme-ODN complex formation
Non-denaturing gel shift assays were used to evaluate the stability of complexes formed
between M.HhaI and 32P-radiolabeled-2P-ODN. After a 30 min incubation to allow formation
of binary (M.HhaI:ODN) or ternary (M.HhaI:ODN:AdoMet or AdoHcy) complexes, a 100-
fold excess of unlabeled 2P-ODN was added to each reaction mixture and incubated for up to
48 h. At the indicated time points (Figure 5A), bound 2P-ODN was separated from unbound
ODN by PAGE [34]. In the absence of cofactor, ~80% of the input 2P-ODN was bound in
binary complexes within 30 min. Addition of either AdoMet or AdoHcy increased the amount
of enzyme-ODN complex to ~90%. However, the stability of these complexes was significantly
increased compared to those without cofactor. Addition of 100-fold molar excess of unlabeled
2P-ODN decreased the percent of ODN bound in binary complexes by ~20% within 10 min,
and by >80% in 48 h (Figure 5A, lanes 1-7). Both the initial decrease in ODN binding (5-10%)
and the rates of dissociation were slower for ternary complexes containing either AdoMet
(Figure 5, lanes 8-14) or AdoHcy (Figure 5, lanes 15-21).
The t1/2 dissociation rate calculated from the data plotted in Figure 5B was ~20 h for binary
complexes and 70-75 h for ternary complexes (Table 1). No significant difference was detected
between the effects of AdoMet and AdoHcy on complex stability. These results contrast with
those obtained with ZCyt-ODNs (Table 1). Both binary complexes with ZCyt-ODNs and
ternary complexes containing ZCyt-ODNs and AdoMet were ~5 fold more stable than binary
and ternary complexes formed with 2P-ODNs. However, ternary complexes containing ZCyt-
ODNs and AdoHcy were 15 fold more stable than those formed with AdoHcy and 2P-ODN
[12, 34]. The increased stability of M.HhaI:2P-ODN complexes in either the presence of
AdoMet or AdoHcy demonstrates that, similarly to what has been reported for both 5,6-
dihydro-5-azacytosine (DZCyt) and ZCyt [34, 38], inhibition of M.HhaI by DNA containing
2-(1H)-pyrimidinone in place of the C targeted for methylation does not require transfer of a
methyl to the 5-position of the pyrimidine ring.
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Stability of Dnmt1:DM72P18 complexes could not be accurately evaluated by electrophoresis
on non-denaturing gels due to aggregation of enzyme and ODN in the loading wells. However,
both M.HhaI and Dnmt1 form tightly closed complexes with ODN inhibitors that are stable to
PAGE under denaturing conditions [see references [34] and [42] for detailed description]. This
method was used to directly compare the stability 2P-ODN binding to M.HhaI (Figure 6A)
and DM72P18 binding to Dnmt1 (Figure 6B). In order to determine complex stability at
temperatures greater than 70 °C (a measure of the stability of a covalent bond between DNA
methyltransferase and its substrate), each methyltransferase was incubated for 30 min at 37 °
C with a 2.5-fold molar excess of radiolabeled 2P-ODN (M.HhaI) or DM72P18 (Dnmt1).
Reactions were then heated to the indicated temperatures for 5 min in SDS loading buffer (with
a final concentration of 1% (v/v) SDS, 1% (v/v) BME) prior to SDS-PAGE. Both M.HhaI
(Figure 6, panel A) and Dnmt1 (Figure 6, panel B) formed detectable complexes. In both cases,
a small enhancement of complex formation was observed in the presence of cofactor (Compare
lane 1 with lanes 2-3 in both panels). Similarly to complexes formed between M.HhaI and
ZCyt-ODNs [34], complexes of M.HhaI with 2P-ODN migrate more rapidly in denaturing gels
than free enzyme. Open ODN:enzyme complexes, characterized as having a slower mobility
in non-denaturing gels than closed complexes [34,38], dissociate in the presence of SDS and,
unless covalently linked are not detectable in denaturing gels [34,42]. Heating at ≥50 °C led
to almost complete dissociation of binary closed complexes of M.HhaI with 2P-ODN (Figure
6, Panel A, lane 7). At 80 °C, ternary closed complexes containing M.HhaI, 2P-ODN and
AdoHcy dissociated, but those containing AdoMet remained intact (Figure 6, Panel A, lanes
14 & 15). This interaction was lost at 95 °C, and substrate binding was no longer detectable.
Ternary complex stability after heating at temperatures >50 °C in presence of SDS and reducing
agents suggests formation of a stable covalent bond between M.HhaI and 2P-ODN. Ternary
complexes between M.HhaI and ZCyt-ODN were similarly stable to heating in the presence
of SDS and reducing agents, but dissociated at 75 °C, presumably due to disruption of the
integrity of the pyrimidine ring in a manner that prevents rebinding to the enzyme (33, 40).
In contrast, Dnmt1 forms two distinct complexes with radiolabeled DM72P18 that are stable
in the presence of SDS and BME at room temperature, a closed complex with the mobility of
an ~145kDa protein and a slower migrating, open complex with the mobility of an ~200kDa
protein. Neither complex co-migrates with unbound Dnmt1 (~187kDa). The increased mobility
of the closed complex of Dnmt1 bound to DM72P18 indicates a significant conformational
change, similar to that seen with M.HhaI. However, formation and stability of the Dnmt1:
DM72P18 complex appears to have little dependence on cofactor (Figure 6B). Whether held
on ice or at room temperature, the only difference noted was a slightly lower efficiency of ODN
binding in the faster migrating closed complexes formed in the absence of cofactor (Figure 6,
Panel B, lanes 1-6). Essentially all of the closed complexes were disrupted by heating at 50 °
C(Figure 6, Panel B, lanes 7-9) while the low mobility open complexes proved to have a much
greater stability. These complexes gradually dissociated as the temperature was raised from
50 to 95 °C (Figure 6, Panel B, lanes 7-15). The persistence of a fraction of open
Dnmt1:DM72P18 complex, even at 95 °C, suggests that a small percentage of Dnmt1 is
covalently attached to 2P in a manner that disrupts the compact, closed conformation. This
pattern of complex distribution after SDS-PAGE is similar to that observed between Dnmt1
and DNA containing 5-fluorocytosine (FCyt) in place of a target C [42] suggesting a disruption
of the catalytic pocket by modification of 2P. To further define the characteristics of the open
complex, the same binding assay was performed using a catalytic mutant of Dnmt1
(Dnmt1C1228S) in which the active cysteine was converted to a serine residue. The stability of
the binary and ternary complexes formed with Dnmt1C1228S was identical to that observed
with the wild type Dnmt1 (Figure S3, Supplemental Material). The persistence of the open
complex with both Dnmt1 and Dnmt1C1228S suggests that even though the serine is a weaker
nucleophile than cysteine, it is capable of forming a stable covalent complex with 2P-ODN.
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4. Discussion
The data presented here clearly demonstrate that once incorporated into DNA, zebularine and
5-azacytidine are essentially equivalent as inhibitors of DNA C5-MTases of both bacterial and
mammalian origin. Nevertheless, there are some significant mechanistic and structural
differences between 2P- and ZCyt-ODNs in their interaction with these enzymes that have
implications with regard to their potency in vivo as activators of genes silenced by methylation
and their potential toxicity/mutagenicity.
4.1 Formation and stabilization of 2P-ODN complexes
Despite our findings that 2P- and ZCyt-ODNs are equally effective inhibitors of M.HhaI and
Dnmt1, ternary complexes with 2P-ODNs have a much shorter half life at 22 °C than ternary
complexes with ZCyt-ODNs (t1/2 of 70 and 310 h) [34]. Our results are consistent with the
postulates that 1) the covalent bond formed between 2P and Cys81 of M.HhaI is more readily
reversible than that with ZCyt and 2) some difference in the interaction of ZCyt and 2P with
the amino acids in the catalytic pocket of the enzyme is a critical factor in establishing the
stability of the closed ternary complex.
The formation of a covalent bond significantly affects the stability of the enzyme:ODN
complex. Several different cytosine analogs have been studied. Ternary closed complexes
between M.HhaI:AdoMet and ODNs with DZCyt replacing C (DZCyt-ODNs) are incapable
of forming a covalent bond with M.HhaI, have a comparably lower affinity for M.HhaI, and
have a t½ of < 8 h under the same conditions. FCyt-ODNs have a high affinity for the enzyme
and the complexes they form with DNA methyltransferases are completely stable at 95 °C due
to formation of irreversible covalent bonds. A third class of enzyme:DNA complexes studied
containing either an abasic furan or a carbocyclic ring replacing C (AP-ODNs) form ternary
complexes with high affinity in the presence of AdoMet, that have a t½ of ~180 h [34,43],
despite the fact that a covalent bond cannot be formed. AP-ODN stability is more than twice
that of 2P: M.HhaI:AdoMet complexes. This suggests that the difference in stability of ternary
complexes containing ZCyt and 2P-ODNs is related to differences in the interactions of these
bases with amino acids in the active site pocket in enzyme:DNA:cofactor complex, rather than
relying solely on the stability of covalent bonds. Several x-ray crystallographic studies support
the proposal that differences in the interaction of bases and sugar moieties with amino acids
in the catalytic pocket of DNA methyltransferase can in fact lead to major differences in the
stability of the closed enzyme:DNA complex [44-46].
4.2 SDS-PAGE as a tool for examining enzyme/ODN complexes
A primary criterion we have used for identifying stable covalent bond formation with analogs
for the target C for a DNA methyltransferase is the ability of the enzyme/DNA complex to
withstand heating at ≥75 °C in the presence of SDS and a reducing agent. An ODN with an
abasic target site, i.e., one that cannot form a covalent bond, with a DNA methyltransferase is
completely dissociated between 50 and 75 °C while an irreversible bond (FCyt) is stable at 95°
C. Examination of the temperature stability of M.HhaI/2P-ODN complexes was undertaken to
strengthen the evidence for covalent bond formation [47]. However, our results indicate that
2P:M.HhaI complexes are completely dissociated (i.e., substrate is released) upon heating at
temperatures ≥50 °C in the absence of cofactors (Figure 6, Panel A). Dissociation is not due
to instability of 2P, since 2P:M.HhaI:AdoHcy and 2P:M.HhaI:AdoMet complexes are stable
at this temperature. Only the 2P:M.HhaI:AdoMet complex survives at 80 °C, although it is not
stable at higher temperatures. Since X-ray crystallographic studies clearly demonstrate that a
covalent bond is formed between 2P and the active Cys81 in the catalytic pocket of M. HhaI
in vitro, we postulate that the covalent bond is more easily broken than the bond with FCyt,
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resulting in an enzyme:DNA complex that is unstable under denaturing conditions at
temperature above 80 °C.
Although the catalytic domains of the mammalian and bacterial methyltransferase are quite
homologous, we noted an important difference in their interaction with 2P-ODNs.
DM72P18:Dnmt1 complexes were stable at 37 °C in the presence or absence of co-factor (data
not shown), yet virtually no closed complexes (Figure 6, Panel B) were detected after heating
at 50 °C suggesting that either these closed complexes do not form covalent bonds or that these
bonds are readily reversible. Nevertheless, a small population of “closed” complex was still
detectable, at 95 °C. We could also detect a small fraction (~1%) of complexes with a similar
reduced mobility of open complexes formed by FCyt and M.HhaI or Dnmt1, i.e., complexes
that migrate more slowly than the native enzyme alone [34,42]. This minor fraction of enzyme
complexes is stable at 50 °C, and diminishes slowly as the temperature is increased. However,
some complexes still persist, even when temperature is raised to 95 °C. The low mobility of
these complexes suggests the possibility that the closed complex has been converted into an
open, thermally stable complex with the substrate trapped by covalent bond formation with an
as yet unidentified electrophile following cleavage of the C-S bond with Cys81 (Figure 7B).
Although AdoMet appears to be the most likely electrophile involved and addition of a methyl
group to C is sufficient to destabilize the closed complex (33, 42), we and others have not
detected any transfer of methyl groups to 2P (data not shown, [47]). Moreover, this
conformational change does not require methylation of 2P at the 5-position of the pyrimidine
ring, since it occurs in the presence or absence of the AdoHcy and even in the absence of any
cofactor. This suggests that at least one of the amino acids other than Cys81 in the catalytic
pocket of Dnmt1 plays a role in forming the stable adduct and that this interaction leads to
destabilization of the closed complex. Whether the unusual heat sensitivity of the rapidly
migrating Dnmt1:DM72P18 complex reflects the fact that 2P and the active site cysteine are in
rapid equilibrium between bound and unbound states or that the absence of 4-amino group in
the target base leads to the formation of a different or additional covalent bond remains to be
determined. Nevertheless, it is clear that some highly stable covalent link(s) links are formed
between Dnmt1 and DM72P18 and that they lead to an altered conformation of the
enzyme:substrate complex.
4.3 Zebularine as an epigenetic chemotherapeutic
Zebularine has been under intense study as a potential antitumor agent based on its stability
(half life of >500 h at pH 7.4) and low toxicity compared to ZdCyd [48]. The studies reported
here demonstrate that zebularine, once incorporated into DNA, is as potent as ZdCyd in
activating genes silenced by DNA methylation. However, concentrations of zebularine
sufficient to cause significant reduction in DNA methylation in cultured cells are at least 100
fold higher than those needed for inhibition by ZdCyd. Inhibition of DNA methylation and
slowing of tumor growth in animals required administration of high doses of zebularine over
an extended treatment period[28]. The difference between the two compounds appears to result
from the slow conversion of zebularine to 2'-deoxyzebularine-5'-diphosphate by
ribonucleotidediphosphate reductase [48]. There are a number of other factors that could
contribute to the low toxicity of zebularine in vivo including; zebularine incorporation into
RNA is at least 7-fold higher than into DNA [49], rapid inactivation of zebularine by the liver
enzyme aldehyde oxidase [50], the slow covalent bond formation resulting in a facile reversal
of enzyme:2P-ODN adducts (Section 3.3), and the stability of the pyrimidinone ring relative
to ZCyt.
Inactivation of Dnmt1 by ZCyt in DNA occurs through the formation of covalent enzyme:DNA
adducts that are potentially mutagenic. ZCyt in this complex is in equilibrium with a ring-open
form that can undergo hydrolysis, yielding a structure that can theoretically form a Watson-
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Crick base pair with cytosine [21] and releasing of a formylated (inactive) enzyme (See Ref.
34 for further detail). 2P is extremely stable, with little or no probability of forming a similar
mutagenic lesion. We demonstrate that 2P adducts have a shorter half-life than those formed
by ZCyt, a difference that could also decrease toxicity. In contrast to ZdCyt, 2P can only form
two hydrogen bonds in a Watson-Crick base pair with G, and forms a “wobble” base when
paired with A [51]. Thus, unlike the open ring form of ZCyt, 2P in DNA should not lead to a
significant increase in CG → TA transitions during DNA replication relative to that noted in
DNA from ZCyd treated cells[52,53]. Consequently, strategies to increase incorporation of
zebularine in a dose dependent manner could theoretically increase the potency of the drug
while maintaining a relatively stable enzyme:DNA adduct, thus improving the efficacy of
zebularine as an epigenetic drug.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
The structure of (A) cytidine (Cyd), and its analogs (B) 2-(1H)-pyrimidinone ribonucleoside
(zebularine), (C) 5-azacytidine (ZCyd), and (D) 5-aza-2'-deoxycytidine (ZdCyd). R=ribose
and dR=2'-deoxyribose.
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Figure 2.
Sequence of ODNs used in this study. M=5MeC. Inhibitors have modified target sites that
contain either 5-azacytosine (Z) or zebularine aglycon (2P) bases in place of the cytosine (C)
residue targeted for methylation (underlined).
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Figure 3.
M.HhaI inhibition by 2P-ODN. Reactions containing 8.6 nM M.HhaI, 2.4 μM [methyl-3H]
AdoMet, and indicated amounts of 2P-ODN inhibitor were incubated with increasing
concentrations of substrate. The rate of incorporation of methyl-3H was determined by liquid
scintillation counting. (A) For each concentration the rate was plotted versus the inhibitor
concentration. See Figure S2, Supplemental Material for corresponding Lineweaver-Burk plot.
(B) A Hanes-Woolf plot of the same rate data. Kinetic determinants extrapolated from each
plot are discussed (See Materials and Methods for details). Each reaction was performed in
duplicate. Error bars indicate standard error from the mean of three independent experiments.
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Figure 4.
Dnmt1 inhibition by DM72P18 ODN. Reactions containing 60 nM Dnmt1, 1.3 μM DM7
substrate, and the indicated concentration of DM72P18 inhibitor were incubated at 37 °C. At
the specified times, duplicate 1 μl aliquots were removed from the pre-incubation mixture and
added to an assay mixture containing 0.71 μM [methyl-3H]AdoMet to detect the remaining
enzyme activity as described in Materials and Methods. (A) The percent activity remaining
was plotted versus the pre-incubation time for each concentration of inhibitor. (B) The
calculated t1/2 was plotted versus 1/concentration of ODN inhibitor. kinactivation=ln2/slope and
kI=-1/x-intercept.
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Figure 5.
Dissociation of 2P-ODN from M.HhaI. (A) Binding reactions containing 45 nM 32P-end
labeled 2P-ODN, 108 nM M.HhaI, 75 ng poly dAdT:dAdT, and 100 μM cofactor (as indicated)
were incubated at 22 °C for 30 min. A 100-fold excess unlabeled 2P-ODN was added to all
reactions with the exception of those in lanes 1, 8, and 15, and the incubation continued for the
indicated times. Zero time points (lanes 2, 9, and 16) represent reactions in which the unlabeled
ODN was added immediately before loading onto a non-denaturing polyacrylamide gel. The
percent bound ODN (% bound) was determined by imaging of the dried gel on a Typhoon
PhosphoImager (Amersham). (% bound = [counts in enzyme-ODN complex/counts in enzyme-
ODN complex + counts in free ODN] X 100). (B) The off rate was calculated by plotting the
ln (specific binding) versus the time of incubation in the presence of cold competitor. A
summary of the data is presented in Table 1.
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Figure 6.
Analysis of M.HhaI and Dnmt1 binding to ODNs containing 2P by SDS-PAGE. (A) M.HhaI:
2P-ODN complexes were formed in reactions containing 2.5 nM M.HhaI, 50 nM 32P-labeled
2P-ODN, and cofactor (100-200 μM). After a 30 min incubation at 37 °C, reaction mixtures
were held at the indicated temperatures in SDS loading buffer (final concentration of 1% SDS,
1% BME) for 5 min prior to electrophoresis. (B) Dnmt1-ODN (DM72P18) complexes were
formed in reactions containing 0.4 μM Dnmt1, 1 μM 32P-labeled DM72P18, and cofactor
(100-200 μM)) and treated as described above. See text for details. Note that samples in Panel
B 1-6 were electrophoresed on a separate gel from samples 7-15. Arrows indicating open (O)
and closed (C) complexes in each gel are placed on the closest side of the gel.
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Figure 7.
(A) Formation and reversal of 2-(1H)-pyrimidinone adduct with the activated thiol of a DNA
C5-MTase. Our data suggests that heating shifts the equilibrium to the left of the reaction.
(B) Formation of a stable adduct after reacting with an undetermined electrophile within the
catalytic pocket of Dnmt1.
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Table 1
Summary of dissociation experiments of M.HhaI-ODN complex
Cofactor
2P-ODN ZCyt-ODN
koff(hours
-1) t1/2 (hours) t1/2 (hours)
None 0.0349 20 110
AdoMet 0.0099 70 310
AdoHcy 0.0092 75 1100
For dissociation analysis, the natural log of the percent bound in the M.HhaI:2P-ODN complex was plotted versus the time of competition of pre-formed
complexes containing radio labeled 2P-ODN with unlabeled 2P-ODN (Figure 5B).
The koff (= -slope) and the t1/2 (=0.693/koff) were calculated from this plot. The t1/2 values for ZCyt-ODN in the presence and absence of cofactor are
presented for comparative purposes [34].
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